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Introduction
The development and clinical use of HIV-protease inhibitors has contributed greatly to treatment of HIV-AIDS as a critical component of highly active anti-retroviral therapy (HAART) regimens.
With this efficacy has come recognition of an associated syndrome of metabolic side-effects which is relevant in evaluating the long-term risk/benefit of treatment options (Calza et al., 2004) . The constellation of metabolic problems with protease inhibitors includes hyperlipidemia, insulin resistance, peripheral lipoatrophy, central fat accumulation, and hepatic steatosis. Despite several hypotheses to explain clinical findings, the cellular and molecular mechanisms underlying this lipodystrophy-like syndrome are incompletely understood. Recent clinical studies in patients (Calza et al., 2004; Woerle et al., 2003) and in normal subjects (Noor et al., 2004; Noor et al., 2002; Purnell et al., 2000) have confirmed a direct connection between some protease inhibitors and metabolic effects, despite the complexity of multi-drug therapy and virological and immunological responses during HAART. The recent emergence of a newer generation of protease inhibitor which exhibits antiviral efficacy without adverse affects on lipid or glucose parameters in the clinic Haas et al., 2003; Murphy et al., 2003; Noor et al., 2004; Sanne et al., 2003; Squires et al., 2004) provided an opportunity to reexamine the molecular pharmacology and toxicology of the protease inhibitor class.
Previous studies revealed that protease inhibitors interfere with key intracellular processes regulating glucose and lipid metabolism in major insulin responsive tissues. Several protease inhibitors directly inhibit glucose transporter activity in adipocytes, in particular GLUT4 which is essential for normal insulin-responsive glucose uptake in adipose and muscle (Hertel et al., 2004; Hruz et al., 2001; Murata et al., 2000) . Differential inhibition of GLUT4 is believed to explain This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on March 8, 2005 as DOI: 10.1124 at ASPET Journals on June 21, 2017 molpharm.aspetjournals.org Downloaded from differences between HIV protease inhibitors on insulin-stimulated glucose disposal in clinical studies using the euglycemic hyperinsulinemic clamp technique (Noor et al., 2004; Noor et al., 2002) .
Protease inhibitors also appear to influence lipid and cholesterol metabolism by inhibiting the degradation of the key transcription factors which control lipid pathways, the sterol regulatory element binding proteins (SREBPs). Degradation of nuclear SREBPs by the proteasome was directly demonstrated in mammalian cells (Hirano et al., 2001) , and proteasome activity was unexpectedly shown to be inhibited by some HIV protease inhibitors in vitro. (Pajonk et al., 2002; Schmidtke et al., 1999) However, effects of HIV protease inhibitors on SREBP levels, translocation, and on SREBP-targeted lipogenic gene expression in liver and adipose tissue have proven to be complex. (Caron et al., 2003; Dowell et al., 2000; Hui, 2003) Further insight into the role of proteasome came from studies showing that processing of apolipoprotein B by proteasome activity in hepatocytes is perturbed by HIV protease inhibitor treatment in HepG2 cells (Liang et al., 2001) , which could contribute to dyslipidemia.
Interference with proteasome function could underlie the lipid effects of protease inhibitors to a greater extent than previously suggested. The surveillance function of proteasome coordinates protein synthesis, folding, and trafficking in the endoplasmic reticulum (ER), and its disruption triggers an adaptive mechanism termed the unfolded protein response (UPR) or more generally the ER stress response. This includes activation of transcription factors and downstream effectors including ER chaperones and amino acid and protein metabolic enzymes (Kaufman et al., 2002; Travers et al., 2000) . Other physiological factors, notably glucose or nutrient deprivation, influence ER stress and affect the scope and extent of the transcriptional response. (Kaufman et al., This article has not been copyedited and formatted. The final version may differ from this version. 2002) Recently it was reported that ER stress is exacerbated by intracellular lipid deposition, and that obesity and metabolic disturbances are closely linked to ER stress and its consequences in both adipose tissue and liver (Ozcan et al., 2004) .
The topology and localization of lipid synthetic enzymes in the ER suggested that further investigation of the relationship between the ER stress response and lipogenesis could provide new insights into protease inhibitor associated lipid disorders. As first described in preliminary reports (Parker, 2003) , these studies revealed a deeper mechanistic link between cellular adaptive responses to protease inhibitors and the transcriptional regulation of lipid metabolism in adipocytes and hepatocytes. The results of these experiments contribute to an integrated mechanism extending previous hypotheses, and help to explain the differences in metabolic profiles observed among the HIV protease inhibitors in clinical use.
This article has not been copyedited and formatted. The final version may differ from this version. Glucose transporter (GLUT) assay. 3T3-L1 adipocytes were incubated with protease inhibitors in Krebs-Ringer Hepes buffer with 2% fetal bovine serum for 30 min, followed by addition of 1µM insulin for 20 min, and then GLUT activity was assayed as uptake of [3H]2-deoxyglucose for 10 min essentially as described previously (Murata et al., 2000) . Primary adipocytes followed the same protocol except that the buffer was supplemented with 2% albumin.
FPLC Superose-6 isolation and assay of proteasome activity. Native proteasome fractions were prepared from cultures of HepG2 cells and 3T3-L1 cells (as undifferentiated preadipocytes)
following the method of Rodgers et al. (Rodgers and Dean, 2003) , briefly as follows. Cells grown in 225 cm2 flasks were harvested at 80-90% confluency, and cells were lysed by shaking for 30 min at 4 degrees C in 20 mM Tris-HCl, pH 7.5, with 10% glycerol, 5 mM ATP, and 0.2% NP-40 (buffer A). Lysates were centrifuged at 10,000 X G for 10 min and the supernatant was collected and concentrated 10-fold in Centricon Plus-20 centrifuge filters (100 kD MW cutoff), followed freezing at -80 degrees. Aliquots (150 µL) of once-thawed concentrates were chromatographed by gel filtration on an AKTA FPLC system using Superose-6 gel filtration in buffer A at 0.50 mL/min, and fractions of 300 µL were collected at 20 degrees C. For the assay of proteasome activity, 10 µL aliquots of each FPLC fraction were incubated in 96-well plates containing 20 mM Tris-HCl ph 7.5 with or without respective inhibitors added with mixing to provide final concentrations indicated in Figures, and a final DMSO level of 0.1%, in a total volume of 100 µL.
The enzyme assay was then initiated by addition of the fluorogenic protease substrate succinyl-7-amino-4-methylcoumarin (suc-LLVY-amc) at 50 µM (final), mixing, and incubation at 37 degrees This article has not been copyedited and formatted. The final version may differ from this version. C for 45 min, followed by determination of amc product fluorescence in a Cytofluor-2 plate reader at 380ex/460em. Product formation was linearly proportional to time and enzyme concentration.
Proteasome activity units are defined as relative fluorescence of LLVY-amc product per assay under these conditions. Purified human erythrocyte 20S proteasome preparations were obtained from Chemicon Intl. (cat # APT280). Aliquots of 20S proteasome were incubated with protease inhibitors in vitro, followed by the assay of chymotryptic proteolytic activity using the fluorogenic substrate suc-LLVY-AMC as described above and essentially according to (Schmidtke et al., 1999) . Reaction rates were determined over a 30 min incubation period and percent inhibition was calculated.
RNA isolation. Total cellular RNA was isolated from cultured HepG2, TC5, and 3T3-L1 cells, using the standard Qiagen method including treatment with DNase. cDNA and cRNA were generated from the cellular RNA using Invitrogen and Enzo LifeScience methods for gene expression profiles and RT-PCR.
Transcriptional profiling. Affymetrix gene profiling (Human U133A chips, with 22214 total RNA sequences profiled; and murine U74Av2 chips with 12422 RNA sequences) was conducted to assess gene expression. RNA samples were isolated from triplicate cell incubation samples (HepG2) or from duplicate cell incubation samples repeated twice (adipocytes). Affymetrix recommended protocol was used in the generation of cRNA probe and hybridization of chips.
Suite version 5.0 was used to scan and quantitate the chip. Data were evaluated for Affymetrix P call, average change in expression (ratio of mean drug-treated/ mean control), and significance of difference between drug treated and control determined by t test (P<0.01 taken as significant).
Results for key genes were confirmed by real time polymerase chain reaction (RT-PCR).
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Results

Proteasome Inhibition by HIV Protease Inhibitors
Five HIV protease inhibitors currently in clinical use were assayed for inhibition of proteolytic cleavage activity in purified human 20S proteasome samples. Concentration-dependent inhibition of chymotryptic activity was observed at levels >1 µM for several of the protease inhibitors ( Figure 1a ). The rank order and IC50 values for 20S proteasome inhibition were saquinavir (IC50 = 3 µM), nelfinavir (4 µM), lopinavir (9 µM), ritonavir (11 µM), and atazanavir (26 µM). A procedure to isolate and assay 26S/20S proteasome from mammalian cells described previously (Rodgers and Dean, 2003) was adapted to assay the high molecular weight proteolytic activity in FPLC Superose-6 gel filtration fractions isolated from 3T3-L1 and HepG2 cell lysates (Figure 1b ).
The lactacystin-inhibitable fractions were pooled and concentrated, and used as the sources of 26S/20S proteasome to assay the effects of HIV protease inhibitors on the hydrolysis of chymotryptic and tryptic fluorogenic peptide substrates. In proteasome preparations from both cell types, lactacystin inhibited chymotryptic activity potently (IC50 < 1 µM) and tryptic activity moderately (IC50 ~ 20 µM), while MG132 strongly inhibited the tryptic activity (IC50 < 1 µM) (Figure 1c) , consistent with the properties of these well-characterized, high affinity proteasome inhibitors (Rodgers and Dean, 2003; Zimmermann et al., 2000) . In comparison to these controls, the HIV protease inhibitors moderately inhibited proteasome chymotryptic activity at micromolar levels in the HepG2 and 3T3-L1 preparations, with modest differences between compounds observed ( Figure 1c ). Weaker inhibition of tryptic activity was also observed under these conditions ( Figure 1c ).
Effects of Protease Inhibitors on Lipogenesis and Glucose Transport in Adipocyte and
Hepatocyte Models
Before incubation with protease inhibitors, 3T3-L1 adipocytes were first differentiated for 5 days to reach a distinct lipid storage droplet morphology with an avid triglyceride biosynthesis rate.
Under these conditions, exposure to HIV protease inhibitors at micromolar concentrations for 24 hours suppressed adipocyte triglyceride synthesis, assayed as the incorporation of [ 14 C]-acetate precursor at the end of the incubation (Figure 2a ). Varying potencies were observed for the five protease inhibitors tested. In time course studies (up to 48 hours), the decrease in cellular lipid biosynthesis was time-dependent with greatest effect at 24 hr incubation ( Figure 2b ). Under these conditions protease inhibitors did not affect cellular ATP levels suggesting that they were not cytotoxic.
In adipose tissue, glucose uptake is required for glycolysis, yielding energy and lactate as well as provision of glycerol-3-phosphate (through the action of glycerol-3-phosphate dehydrogenase on dihydroxyacetone phosphate) essential as precursor for the triglyceride backbone. In 3T3-L1 adipocytes under conditions similar to those used to assay lipogenesis, the protease inhibitors acutely inhibited 2-deoxyglucose uptake assayed in the presence of insulin, with different magnitudes of glucose transport inhibition seen with each protease inhibitor ( Figure 2c ). The 3T3-L1 cells under these conditions expressed approximately equal levels of both GLUT4 and GLUT1
mRNA. To better evaluate GLUT4-dependent effects, additional studies were conducted using primary rat adipocytes which express relatively high levels of GLUT4. In the primary adipocytes, ritonavir acutely inhibited insulin-stimulated glucose transport to a level near the insulin-free control value ( Figure 2d ). Lactate released into the medium by the adipocytes over a 6 hr incubation was concomitantly inhibited by ritonavir in parallel incubations, while atazanavir was This article has not been copyedited and formatted. The final version may differ from this version. essentially without effect on either endpoint ( Figure 2d ). These data demonstrate that protease inhibitors differentially inhibit GLUT4 mediated glucose uptake by adipocytes, and limit the intracellular availability of glucose resulting in diminished formation of a glucose-derived metabolite, lactate.
In contrast to the suppression observed in adipocytes, in HepG2 cells protease inhibitors tended to increase lipogenesis. Triglyceride biosynthesis rate was elevated to varying degrees by the five compounds studied over 3 to 30 µM at 24 hr, and 6 to 48 hr at 10 µM ( Figure 2e ). Cholesterol synthesis under the same conditions in HepG2 cells did not change or was modestly increased (up to 20% increase over control). No effect on cellular ATP levels was observed under these conditions, suggesting the lack of cytotoxicity. The increases in lipogenesis in HepG2 cells were observed at concentration ranges of the protease inhibitors which resulted in proteasome inhibition in vitro, although the apparent potencies in the two assays were only roughly correlated. Unlike the adipocytes, under conditions in which lipid synthesis was affected, glucose uptake was not significantly affected by any of the protease inhibitors studied in HepG2 cells. The lack of glucose transport inhibition is consistent with the finding that HepG2 cells express GLUT3 and GLUT1, which are relatively insensitive to inhibition by HIV protease inhibitors, but do not express GLUT4 which is sensitive.
Gene Expression Profiles in Hepatocyte and Adipocyte Models
Affymetrix gene expression profiling was conducted to further evaluate cellular and molecular adaptive responses to the effects of protease inhibitors. Cells were treated for 24 hr with vehicle control or protease inhibitors under the conditions used in the functional assays, followed by (Table 1) . Multiple genes for amino acid biosynthesis and transport, amino acyl tRNA synthetases, glutathione metabolism, and chaperones such as the DnaJ/HSP40 homologs involved in the ER stress response were also induced (Table 1) . Other genes involved in proteasome and ER function were also induced, including ubiquitin ligase, stanniocalcin-2, calmegin, and exportin T. Suppression of serum and glucocorticoid-regulated kinase (SGK), a regulator of the E3 ubiquitin-protein ligase (Nedd4-2) was observed. The magnitudes of change in ER stress and UPR gene expression in HepG2 cells were lower for atazanavir than the other protease inhibitors tested (Table 1) .
Lipogenic Gene Expression in Coordination with ER Stress Response
The ER stress response to HIV protease inhibitors in HepG2 cells was associated with moderate but significant increases in mRNA encoding several enzymes of fatty acid and cholesterol This article has not been copyedited and formatted. The final version may differ from this version. lipid/metabolic pathways were observed in time courses (Fig 4a) . Marked, rapid increases in mRNA for ATF4 (to 15-fold), GADD153 (to 12-fold), and CEBP/β (to 6-fold) were observed for nelfinavir, ritonavir, and lopinavir in the hepatocyte cell line, while atazanavir treated cells remained relatively quiescent over the 32 hr time course (Fig 4a) . These changes were closely followed by induction of asparagine synthetase (up to >60-fold with nelfinavir), ACC-α (to 4-fold with ritonavir), and PEPCK (to 25-fold with lopinavir).
Down-regulation of Lipogenesis Genes in Adipocytes
The expression profile in adipocytes revealed induction of transcription factors and mediators of the ER stress response (ATF3, GADD153, ATF4, and GADD45), enzymes of amino acid, glutathione, and protein metabolism, and other components of the ER stress response, consistent
This article has not been copyedited and formatted. The final version may differ from this version. with proteasome inhibition and the UPR (Table 2) . However, in contrast to the hepatocyte models, the key lipogenic transcription factors (PPAR-γ and SREBP-1c) and multiple enzymes of the lipid biosynthesis pathways were down-regulated in the adipocytes (Table 2) vitro and decrease protein degradation in cells (Gaedicke et al., 2002; Pajonk et al., 2002; Schmidtke et al., 1999) . Our findings support the idea that protease inhibitors, nanomolar inhibitors of the HIV protease, are micromolar modulators of mammalian proteasome function and specificity, and at therapeutic levels can significantly affect processing and trafficking of specific proteins in the cell and trigger a counter-regulatory response.
Our observations are consistent with previous reports implicating interference by HIV protease inhibitors with processing of nuclear transcription factors SREBP-1 and -2, C/EBP-α, and PPAR- Caron et al., 2003; Dowell et al., 2000; Hui, 2003) . Proteolytic events control SREBP processing in the ER and Golgi as well the nucleus (Hirano et al., 2001) . Nuclear turnover of SREBP was shown to be blocked by ritonavir in liver and adipose leading to observed increases in Table 1 . Transcriptional profile in protease inhibitor-treated HepG2 cells. HepG2 cells were treated with nelfinavir (3 and 10 µM), ritonavir (10 and 30 µM), or atazanavir (10 and 30 µM) for 24 hr under the conditions used in the lipid synthesis assays. Cells were washed and RNA was isolated from triplicate cell incubations and gene expression profiles were conducted using the Affymetrix protocol. All genes with significant changes in expression for one or more of the treatments are included in the table. Data are expressed as mean mRNA concentration ratio of treated/control for treated/ control for atazanavir 30 µM, ritonavir 30 µM, and nelfinavir 10 µM.
Results are grouped by gene function. Significant differences from control, a indicates P < 0.01. 
Figure 4b
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